Via: Endovascular Today
November 29, 2017—Silk Road Medical, Inc. announced data from the ROADSTER 1 and 2 trials demonstrating the safety and efficacy of the company’s Enroute transcarotid neuroprotection and Enroute transcarotid stent system, which are specifically designed and indicated for transcarotid artery revascularization (TCAR). The data were first presented at the 2017 VEITHsymposium, held November 14–18 in New York, New York.
Peter Schneider, MD, National Coprincipal Investigator of the ROADSTER 2 postmarket study of the Enroute system, commented in the company's announcement, “TCAR is the next step. Carotid endarterectomy has been perfected over 50 years, but no matter how good it gets, it has certain inherent challenges that aren’t ever going to go away. My attitude now has really flip-flopped from that of tried-and-true surgery to what I think is the future of carotid artery repair.”
Read More: http://evtoday.com/2017/11/updated-tcar-data-presented-from-silk-road-medicals-roadster-1-and-2-studies/
RSS Feed
